RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 CETP Inhibitor Evacetrapib Reduces LDL-C and Raises HDL-C Levels
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 15
SP 15
OP 16
DO 10.1177/155989771115009
UL http://mdc.sagepub.com/content/11/15/15.abstract
AB Results from a Phase 2 randomized controlled trial of the novel cholesteryl ester transfer protein (CETP) inhibitor evacetrapib are discussed. Compared with placebo or statin monotherapy, evacetrapib with or without a statin increased high-density lipoprotein cholesterol (HDL-C) and decreased low-density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia [Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or with Statins on HDL and LDL Cholesterol Trial; NCT01105975].